Of the first 150 tumor samples tested in the clinical lab, 90 (60%) had an identifiable mutation, which were 38% BRAF, 15% NRAS, 4% GNAQ, 2% KIT, and ∼1% CTNNB1. Now with additional prospective testing for over 15 months, the numbers remain similar in their breakdown. Here, NRAS is linked to neoplasm.